New hope for chinese men with advanced prostate cancer?

NCT ID NCT03523442

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-stage study tests the drug apalutamide in 19 Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. Researchers want to see how the drug behaves in the body and if it is safe. They will also check if it lowers PSA levels, a marker of cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide
What this could lead to: If successful, this could confirm that apalutamide is safe and works similarly in Chinese patients, supporting its use for controlling advanced prostate cancer.
What could go wrong: This is a very early, small study with only 19 participants. It focuses on safety and drug levels, not on proving the drug works. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Beijing Cancer Hospital of Peking University

Beijing, 100142, China
Fudan Cancer Hospital

Shanghai, 200032, China
Jiangsu Cancer Hospital

Nanjing, 210000, China
Peking University Third Hospital

Beijing, 100083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.